NPIL Research and Deveopment (NRDL), which was recently demerged from Nicholas Piramal India, has commenced Phase-1 studies of a new experimental drug molecule, P1 201-07, in The Netherlands.
The company had submitted the clinical trial application (CTA) for P1201-07 to the central committee on research involving human subjects (CCMO), the regulatory authority of The Netherlands and the independent ethics committee of the foundation Evaluation Of Ethics in Biomedical Research (BEBO), Assen, The Netherlands. Both the bodies have approved the company's application to initiate Phase-I study of P1201-07.
"This is our fourth new drug to enter the clinic and the first from the research collaboration with pharma major Eli Lilly. The drug development timeline is on schedule. We in-licensed this molecule from Lilly in January 2007, and it has gone to the clinic in just a year," said Dr. Swati Piramal, director, strategic alliances & communications, NPIL.
No comments:
Post a Comment